Anti-YY1 antibody [EPR4651] - Nuclear Loading Control,Abcam,AB109228

Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .

Host

Rabbit

Reactivity

Human

Application

IHC-P, WB

Platform ID

BAB266871134

Abcam

Headquarters

Discovery Drive Cambridge Biomedical Campus Cambridge CB2 0AX UK

Contact

Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215

Product Specifications
Scientific Background

Specifications

NameAnti-YY1 antibody [EPR4651] - Nuclear Loading Control
Cat. No.AB109228
HostRabbit
IsotypeIgG
ReactivityHuman
ApplicationIHC-P, WB
ClonalityMonoclonal
Clone NumberEPR4651
Concentration0.111 mg/mL Batch dependent concentration
ImmunogenThe exact immunogen used to generate this antibody is proprietary information.
PurityAffinity purification Protein A
Appearance/FormLiquid
ShippingBlue Ice
FormulationpH: 7.2 - 7.4 Preservative: 0.05% Sodium azide Constituents: 50% Tissue culture supernatant, 40% Glycerol (glycerin, glycerine), 9.85% Tris glycine, 0.1% BSA
Storage-20°C
Regulatory StatusResearch Use Only

Scientific Background

Target data Multifunctional transcription factor that exhibits positive and negative control on a large number of cellular and viral genes by binding to sites overlapping the transcription start site (PubMed : 15329343, PubMed : 17721549, PubMed : 24326773, PubMed : 25787250). Binds to the consensus sequence 5'-CCGCCATNTT-3'; some genes have been shown to contain a longer binding motif allowing enhanced binding; the initial CG dinucleotide can be methylated greatly reducing the binding affinity (PubMed : 15329343, PubMed : 17721549, PubMed : 24326773, PubMed : 25787250). The effect on transcription regulation is depending upon the context in which it binds and diverse mechanisms of action include direct activation or repression, indirect activation or repression via cofactor recruitment, or activation or repression by disruption of binding sites or conformational DNA changes (PubMed : 15329343, PubMed : 17721549, PubMed : 24326773, PubMed : 25787250). Its activity is regulated by transcription factors and cytoplasmic proteins that have been shown to abrogate or completely inhibit YY1-mediated activation or repression (PubMed : 15329343, PubMed : 17721549, PubMed : 24326773, PubMed : 25787250). For example, it acts as a repressor in absence of adenovirus E1A protein but as an activator in its presence (PubMed : 1655281). Acts synergistically with the SMAD1 and SMAD4 in bone morphogenetic protein (BMP)-mediated cardiac-specific gene expression (PubMed : 15329343). Binds to SMAD binding elements (SBEs) (5'-GTCT/AGAC-3') within BMP response element (BMPRE) of cardiac activating regions (PubMed : 15329343). May play an important role in development and differentiation. Proposed to recruit the PRC2/EED-EZH2 complex to target genes that are transcriptional repressed (PubMed : 11158321). Involved in DNA repair (PubMed : 18026119, PubMed : 28575647). In vitro, binds to DNA recombination intermediate structures (Holliday junctions). Plays a role in regulating enhancer activation (PubMed : 28575647). Recruits the PR-DUB complex to specific gene-regulatory regions (PubMed : 20805357).. Proposed core component of the chromatin remodeling INO80 complex which is involved in transcriptional regulation, DNA replication and probably DNA repair; proposed to target the INO80 complex to YY1-responsive elements. See full target information YY1

Category Paths

Request a product

Please provide the required information below so that we can quickly source your products.